Shares of Matinas Biopharma Holdings, Inc. (NYSE:MTNB – Get Free Report) were down 6.6% during trading on Tuesday . The stock traded as low as $0.53 and last traded at $0.56. Approximately 46,870 shares changed hands during trading, a decline of 74% from the average daily volume of 182,658 shares. The stock had previously closed at $0.60.
Matinas Biopharma Stock Down 1.0 %
The firm has a market cap of $2.87 million, a PE ratio of -0.12 and a beta of 1.54. The business has a fifty day moving average of $0.58.
Matinas Biopharma Company Profile
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D.
Further Reading
- Five stocks we like better than Matinas Biopharma
- How to Effectively Use the MarketBeat Ratings Screener
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Top 3 Beverage Stocks Pouring Out Profits
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
-ltd-logo-1200x675.jpg?v=20230317161434&h=45&w=95&zc=2){kind=logo}
